SCHEDULE 13G: L1 Capital Global Opportunities Master Fund Discloses 6.78% Stake in Helius Medical Technologies

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 6.78% beneficial ownership stake in Helius Medical Technologies, Inc., as detailed in a recent Schedule 13G filing.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G, indicating beneficial ownership of Helius Medical Technologies, Inc. common stock.
• The fund beneficially owns 214,050 shares of common stock, representing 6.78% of the class.
• This percentage is calculated based on 3,155,111 common shares outstanding after a recent offering, as disclosed in the Issuer's Prospectus filed on June 6, 2025.
• The filing also notes that 214,050 warrants are held but are subject to a 4.99% beneficial ownership limitation and are not included in the reported common stock ownership.
• The filing states the event requiring this statement occurred on June 6, 2025.
• The reporting person is a passive investor, certifying that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing itself is neutral, as it is a factual disclosure. However, the disclosure of a new significant institutional investor taking a stake can be perceived as a moderately positive signal of confidence in the company, especially following a recent offering.

Positives

• A significant institutional investor, L1 Capital Global Opportunities Master Fund, Ltd., has taken a 6.78% stake in Helius Medical Technologies, Inc., potentially signaling confidence in the company's prospects.

Risks

• The 214,050 warrants held by L1 Capital are subject to a 4.99% beneficial ownership limitation, meaning they cannot be exercised to exceed this threshold without further disclosure or regulatory considerations.

Future Outlook

The document does not contain any forward-looking statements or guidance from Helius Medical Technologies, Inc. or the reporting person regarding the company's future performance.

Industry Context

This filing indicates a significant investment by a global opportunities fund in a healthcare technology company, Helius Medical Technologies, Inc., which operates in the medical device sector. The filing itself does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor could be viewed positively, potentially increasing investor confidence and market liquidity. The recent offering implies dilution for existing shareholders if they did not participate.

Key Dates

Keywords

Helius Medical Technologies, L1 Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Healthcare Technology, Medical Devices, SEC Filing